SAN FRANCISCO--(BUSINESS WIRE)--Invitae Corporation (NYSE:NVTA), a genetic information company, today announced that it has expanded its genetic testing offering with hundreds of additional genes and ...
Mutations to the BRCA1 and BRCA2 genes significantly increase the chances of breast and ovarian cancers, and a test can assess a person’s risk from those variants. But those genes are just two of the ...
(RTTNews) - The U.S. Food and Drug Administration granted de novo marketing authorization for Invitae's Common Hereditary Cancers Panel, an in vitro diagnostic test to help detect dozens of cancer ...
– Helps to detect circulating tumor DNA (ctDNA) as a biomarker in clinical research and clinical trials for solid tumor malignancies – – May provide real-time data on therapy response, support patient ...
Invitae offers testing for hundreds of genes, covering hereditary cancers, epilepsy, arrhythmias, and more. Invitae Corporation, a genetic testing company based in San Francisco, has a lofty goal—to ...
BOSTON--(BUSINESS WIRE)--Outcomes4Me Inc., developer of a leading free mobile app and platform to navigate cancer treatment and care, today announced that it has partnered with Invitae Corporation ...
San Francisco-based genetic testing company Invitae has rolled out a one-price-fits-all payment model for its range of tests, charging a set $475 for any test for patients who don’t go through their ...
Invitae boosted its genetic testing menu with a new test for the diagnosis of spinal muscular atrophy, the second-leading genetic disease in infants. The test provides “significant improvements” over ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results